Clinical trial
A Randomized, Double-blind, Placebo-Controlled Phase 2 Study With Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects With Chronic Pulmonary Sarcoidosis
NCT05314517 is registered in ClinicalTrials.gov with Kinevant Sciences GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-Controlled Phase 2 Study With Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects With Chronic Pulmonary Sarcoidosis
- Lead sponsor
- Kinevant Sciences GmbH
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- August 31, 2022
- Completion date
- April 9, 2025
- Enrollment
- 107 (actual)
- Sites
- 47
Conditions
As the registry lists them; a condition with its own page is linked.